A post-marketing surveillance study of dabrafenib and trametinib combination in Japanese patients with unresectable advanced or recurrent BRAF-mutated NSCLC

T Tomoaki Kaizuka R Ryohei Kurihara Y Yuya Yokochi N Naoko Suenaga

Article Details

Volume / Issue Vol. 15, Issue 1
Published July 02, 2025
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (4)

T

Tomoaki Kaizuka

R

Ryohei Kurihara

Y

Yuya Yokochi

N

Naoko Suenaga